This Wednesday, the pharmaceutical companies Sanofi and GlaxoSmithKline announced that they will request the United States health authorities to approve the vaccine that they worked together against Covid, after receiving the results of the trials carried out on human beings, the which confirmed that it has a high level of protection against the virus.
According to the statement issued by Sanofi and GlaxoSmithKline, the last stage of said study found that 2 doses of their coronavirus vaccine had an effectiveness about 58% to prevent infection, 75% to prevent disease development moderate to severe, and a 100% chance of avoiding severe to fatal cases.
Similarly, both pharmaceutical companies conducted another study to find out the scope of a booster dose of his vaccine, which indicated that it does provide a significant increase in neutralizing antibodies to Covid.
“The evolving epidemiology of Covid-19 demonstrates the need for a variety of vaccines”, said Roger Connor, president of GSK Vaccines, in said letter.
The Sanofi-GSK vaccine uses “a well-established that has been widely applied to prevent infection with other viruses, including pandemic influenza. We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period,” he added.
Now, they will process regulatory approval, both from the Administration Food and Drug Administration (FDA) and the European Medicines Agency.
Both pharmaceutical companies they expected the vaccine to be ready from 2021, but the first trials showed that it produced a somewhat “insufficient” immune response, especially in adults older than 60 years, because it did not have enough material that triggers the production of antibodies that fight diseases.
You may be interested:
COVID Vaccine: what happened to Patria, the Mexican vaccine that AMLO said would be ready in 2021 and why is it delayed